| Literature DB >> 29211250 |
D N Piranda1,2, R B V Abreu1, D R Freitas-Alves1,3, M A de Carvalho1,4, R Vianna-Jorge1,3,5.
Abstract
The inducible inflammatory enzyme cycloxigenase-2 is up-regulated in cancer, and favors tumor progression. Cycloxigenase-2 is encoded by the prostaglandin-endoperoxide synthase 2 (PTGS2) gene, which presents sequence variations in the promoter region (PR) and in the 3'-untranslated region (3'-UTR). Different PR (rs689465, rs689466, rs20417) and 3'-UTR (rs5275) variants were generated by site-directed mutagenesis, and combined in haplotypes to access expression levels using a reporter system (luciferase) in human cells (MCF-7 and HEK293FT). Luciferase activity did not differ significantly among PTGS2 PR constructs, except for pAAC (containing variant allele rs20417 C), with 40% less activity than pAAG (wild-type sequence) in MCF-7 cells (P<0.01). Despite the lack of individual significant differences, PTGS2 PR constructs enclosing rs689466 G (pAGG and pAGC) showed an approximate two-fold increase in luciferase activity when compared to those containing rs689466 A (pAAG, pGAC, pAAC and pGAG) in both cell lines (P<0.001 for MCF-7 and P=0.03 for HEK293FT). The effect of PTGS2 3'-UTR sequences varied between MCF-7 and HEK293FT: MCF-7 cells showed significant reduction (40-60%) in luciferase activity (at least P<0.01), whereas HEK293FT cells showed more diverse results, with an average 2-fold increase when combined constructs (PR and 3'-UTR) were compared to respective parental PR sequences. The contribution of 3'-UTR variant (rs5275) was not consistent in either cell line. Despite the modulation of the 3'-UTR, with variable effects of rs5275, the enhancing transcriptional effect of rs689466 G was still detectable (P<0.0001 in MCF-7 or P=0.03 in HEK293FT cells).Entities:
Mesh:
Substances:
Year: 2017 PMID: 29211250 PMCID: PMC5711006 DOI: 10.1590/1414-431X20176546
Source DB: PubMed Journal: Braz J Med Biol Res ISSN: 0100-879X Impact factor: 2.590
Figure 1.Luciferase activity of constructs containing the promoter region of the PTGS2 gene in MCF-7 cells (panels A and B) or in HEK293FT cells (panels C and D). The results are depicted for each construct (panels A and C) or in relation to rs689466 A/G allele (panels B and D), combining data obtained with constructs pAAG, pGAC, pAAC and pGAG (pNAN) or with pAGG and pAGC (pNGN). Data are reported as the fold variation of luciferase activity in relation to pAAG, and are the means±SD from at least 2 independent transfection experiments, comprising 12 replicates. Statistical analyses were conducted comparing each construct to pAAG (panels A and C), or comparing pNGN versus pNAN (panels B and D). *P<0.05, **P<0.001, ***P<0.0001 (Mann-Whitney U-test and Kruskal-Wallis test with Dunn's post-test).
Figure 2.Luciferase activity of constructs containing the promoter region alone or in combination with the 3′-UTR (rs5275 T or C) of the PTGS2 gene in MCF-7 cells (A) or in HEK293FT cells (B). Data are reported as the fold variation of luciferase activity in relation to pAAG, and are the means±SD from at least 2 independent transfection experiments, comprising 12 replicates. Cells were cotransfected with pGR-TK to normalize transfection efficiency. Statistical analyses were performed within each haplotype triad, i.e. comparing the results between constructs enclosing both PR and 3′-UTR sequences (containing either rs5275 T or C), as well as comparing each full haplotype to their respective parental PR sequence. *P<0.05, **P<0.001, ***P<0.0001 (Kruskal-Wallis test with Dunn's post-test).